Peptide
Octreotide (Sandostatin)
Octreotide is a synthetic octapeptide analog of somatostatin with prolonged action. FDA-approved in 1988, it is available as immediate-release injection and long-acting repeatable (LAR) formulation. Primary indications include acromegaly, carcinoid syndrome, and neuroendocrine tumors. The PROMID trial demonstrated significant antiproliferative effects in midgut neuroendocrine tumors, and multiple trials confirm efficacy for GH/IGF-1 suppression in acromegaly.
- Updated
- How we grade
- 49 studies cited
Research notice. This page is for education and research. Peptides may not be FDA-approved for human use and may only be legally available for research. Talk to a qualified clinician before considering any peptide.
- Best evidence
- Grade A
- Conditions studied
- 2
- Outcomes
- 13
- Graded outcomes
- 6421
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
General
Key findings
- GH Suppression (Acromegaly)Improves (the measure goes down)
- Acromegaly SymptomsImproves (the measure goes down)
- Tumor Progression (NETs)Improves (the measure goes down)
Studies cited
49 studies from PubMed
- Variations in Octreotide Dosing in Published Reports of Sulfonylurea Toxicity: A Systematic Review, 1988-Present.
- The use of octreotide in pediatric patients: Practical applications for gastrointestinal disorders and beyond: A narrative review.
- Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1
- Octreotide efficacy and safety in children with hyperinsulinism: evidence from two Chinese centers.
- Somatostatin Versus Octreotide for Prevention of Postoperative Pancreatic Fistula: The PREFIPS Randomized Clinical Trial: A FRENCH 007-ACHBT Study.
- Oral Octreotide: A Review of Recent Clinical Trials and Practical Recommendations for Its Use in the Treatment of Patients With Acromegaly
- IVIVC of Octreotide in PLGA-Glucose Microsphere Formulation, Sandostatin® LAR.
- The use of high dose octreotide in management of neonatal chylothorax: Review.
- Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study
- Health-Related Quality of Life for Long-Acting Octreotide versus Placebo in Patients with Metastatic Midgut Neuroendocrine Tumors in the Phase 3 PROMID Trial
- Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.
- Long-acting octreotide treatment has no impact on tumor uptake of 99mTc-HYNIC-TOC in patients with neuroendocrine tumors.
- ANNIVERSARY REVIEW: Octreotide, 40 years later.
- Octreotide use and safety in infants with hyperinsulinism.
- Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy.
- Octreotide - A Review of its Use in Treating Neuroendocrine Tumours
- Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial
- Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers.
- Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis
- From somatostatin to octreotide LAR: evolution of a somatostatin analogue
- Octreotide acetate-steroid combination therapy for malignant gastrointestinal obstruction.
- Octreotide for primary moderate to severe acute pancreatitis: a meta-analysis.
- Successful treatment of congenital hyperinsulinism with long-acting release octreotide.
- Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients.
- Sustained-release delivery of octreotide from biodegradable polymeric microspheres.
- Antitumor effects of somatostatin analogs in neuroendocrine tumors
- Octreotide's role in the management of sulfonylurea-induced hypoglycemia.
- Octreotide therapy for hepatocellular carcinoma: a systematic review of the evidence from randomized controlled trials.
- Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group
- Octreotide LAR: safety and tolerability issues.
- Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly
- Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.
- Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
- Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
- Growth hormone binding protein and growth hormone availability in acromegalic patients treated with long-acting octreotide (Sandostatin-LAR).
- Octreotide in hyperinsulinism.
- Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.
- Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group
- Modified method using a somatostatin analogue, octreotide acetate (Sandostatin) to assess in vivo insulin sensitivity.
- Octreotide in gastrointestinal motility disorders.
- The role of octreotide (Sandostatin) in non-growth hormone-, non-thyroid-stimulating hormone-, and non-prolactin-secreting adenomas.
- The effect of somatostatin analog octreotide (Sandostatin) on luteinizing hormone and ovarian steroids in insulin-dependent diabetic women without residual insulin secretion.
- Octreotide and diabetes: theoretical and experimental aspects.
- Proceedings of the discussion, "Tolerability and safety of Sandostatin".
- [Octreotide in intestinal pseudo-obstruction?].
- Potential gastrointestinal uses of somatostain and its synthetic analogue octreotide.
- Debut of a somatostatin analog: octreotide in review.
- Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.
- [Treatment of gastrointestinal neuroendocrine tumors with the somatostatin analog octreotide (Sandostatin)].